XML 47 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 25, 2021
shares
Jan. 04, 2021
USD ($)
Apr. 30, 2021
USD ($)
$ / shares
shares
Mar. 31, 2021
shares
Jan. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Aug. 31, 2021
USD ($)
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Mar. 23, 2021
USD ($)
Jul. 06, 2020
USD ($)
Subsidiary, Sale of Stock [Line Items]                          
Cash and cash equivalents                   $ 146,256,000 $ 102,562,000    
Accumulated deficit                   422,882,000 376,072,000    
Payments for legal settlements                     $ 48,421,000    
Settlement payment from daewoong     $ 25,500,000             25,500,000      
Public Stock Offering                          
Subsidiary, Sale of Stock [Line Items]                          
Number of shares issued in transaction (in shares) | shares     10,350,000                    
Offering price per share (in dollar per share) | $ / shares     $ 9.50                    
Aggregate net proceeds from stock offering     $ 92,426,000                    
Underwriters Option                          
Subsidiary, Sale of Stock [Line Items]                          
Number of shares issued in transaction (in shares) | shares     1,350,000                    
A T M Sales Agreement                          
Subsidiary, Sale of Stock [Line Items]                          
Number of shares issued in transaction (in shares) | shares             934,367            
Aggregate net proceeds from stock offering             $ 10,910,000            
Intellectual Property Disputes, Jeuveau                          
Subsidiary, Sale of Stock [Line Items]                          
Payments for legal settlements           $ 15,000,000       15,000,000      
Intellectual Property Disputes, Jeuveau | Forecast                          
Subsidiary, Sale of Stock [Line Items]                          
Payments for legal settlements               $ 5,000,000 $ 15,000,000        
Pharmakon Term Loans | Term Loan                          
Subsidiary, Sale of Stock [Line Items]                          
Debt instrument, face amount                   125,000,000      
Tranche A Loan | Term Loan                          
Subsidiary, Sale of Stock [Line Items]                          
Debt instrument, face amount                   75,000,000      
Proceeds from issuance of secured debt                   68,695,000      
Tranche B Loan | Term Loan                          
Subsidiary, Sale of Stock [Line Items]                          
Debt instrument, face amount                   $ 50,000,000      
Oxford Term Loan Facility                          
Subsidiary, Sale of Stock [Line Items]                          
Repayments of long-term lines of credit   $ 76,447,000     $ 76,447,000                
Daewoong Convertible Note | Convertible Debt                          
Subsidiary, Sale of Stock [Line Items]                          
Debt instrument, face amount                         $ 40,000,000
Convertible debt                       $ 40,779,000  
Daewoong Convertible Note | Convertible Debt | Common Stock                          
Subsidiary, Sale of Stock [Line Items]                          
Conversion of common shares (in shares) | shares 3,136,869     3,136,869